A multicenter, prospective, single arm, open label ...
The ESPOUSE Study evaluated sTMS for migraine prevention, showing a significant reduction in headache days (−2.75 ± 0.40) and a 46% responder rate. Adverse events were minor, with no serious events reported. sTMS is effective and well-tolerated for migraine prevention.
Related Clinical Trials
Reference News
A multicenter, prospective, single arm, open label ...
The ESPOUSE Study evaluated sTMS for migraine prevention, showing a significant reduction in headache days (−2.75 ± 0.40) and a 46% responder rate. Adverse events were minor, with no serious events reported. sTMS is effective and well-tolerated for migraine prevention.